Market capitalization | $309.89m |
Enterprise Value | $285.96m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.23 |
P/S ratio (TTM) P/S ratio | 14.34 |
P/B ratio (TTM) P/B ratio | 3.65 |
Revenue growth (TTM) Revenue growth | 389.82% |
Revenue (TTM) Revenue | $21.61m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a XOMA Corporation forecast:
3 Analysts have issued a XOMA Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 22 22 |
390%
390%
|
|
Gross Profit | 21 21 |
511%
511%
|
|
EBITDA | -15 -15 |
29%
29%
|
EBIT (Operating Income) EBIT | -15 -15 |
31%
31%
|
Net Profit | -30 -30 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Head office | United States |
CEO | Owen Hughes |
Employees | 13 |
Founded | 1981 |
Website | www.xoma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.